=> fil reg
FILE 'REGISTRY' ENTERED AT 09:36:13 ON 03 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 JUN 2005 HIGHEST RN 851509-21-2 DICTIONARY FILE UPDATES: 1 JUN 2005 HIGHEST RN 851509-21-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

* The CA roles and document type information have been removed from * the IDE default display format and the ED field has been added, * effective March 20, 2005. A new display format, IDERL, is now * available and contains the CA role and document type information. * *

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at: http://www.cas.org/ONLINE/DBSS/registryss.html




VAR G1=CH2/8 NODE ATTRIBUTES: DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE

L17 44013 SEA FILE=REGISTRY SSS FUL L15

L21 STR



jan delaval - 3 june 2005

VAR G2=CHO/19/22/27/OH VAR G3=CH2/30 VAR G4=19/OH/AK/33/X/35/32 NODE ATTRIBUTES: CONNECT IS M1 RC AT 6 CONNECT IS M1 RC AT 12 CONNECT IS M1 RC AT 32 DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 32

STEREO ATTRIBUTES: NONE

L26 276 SEA FILE=REGISTRY SUB=L17 CSS FUL L24 L27 STR 10 12 17 0 G1 CH2 G2-CH2-O 13 5 6 C 0 11 0 15 **@8** CH2-O-- CH2-- CH G1-— O---- СH2-- CH 2 3 19 18 16 @14

VAR G1=CH2/8
VAR G2=4/14
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE

L28 494 SEA FILE=REGISTRY ABB=ON PLU=ON L23 OR L26

L30 152 SEA FILE=REGISTRY SUB=L28 SSS FUL L27

100.0% PROCESSED 494 ITERATIONS

152 ANSWERS

SEARCH TIME: 00.00.01

=> d his

(FILE 'HOME' ENTERED AT 08:38:58 ON 03 JUN 2005) SET COST OFF

FILE 'HCAPLUS' ENTERED AT 08:39:08 ON 03 JUN 2005

L1 3 S (US6838452 OR US20030225035 OR US2004106677)/PN OR (US2003-71

L2 2 S L1 NOT RF/TI

E HARATS D/AU

L3 102 S E3, E4

E DROR/AU

E GEORGE J/AU

L4 700 S E3-E32, E35-E38

ACCESSION NUMBER: 1998:639311 CAPLUS

DOCUMENT NUMBER: 130:50286

TITLE: Stimulation of monocytes and platelets by short-chain

phosphatidylcholines with and without terminal

carboxyl group

AUTHOR(S): Kern, Hartmut; Volk, Thomas; Knauer-Schiefer, Suzanne;

Mieth, Tanja; Rustow, Bernd; Kox, Wolfgang J.;

Schlame, Michael

CORPORATE SOURCE: University Hospital Charite, Department of

Anesthesiology and Intensive Care Medicine, Humboldt-University, Berlin, 10117, Germany

SOURCE: Biochimica et Biophysica Acta (1998), 1394(1), 33-42

CODEN: BBACAQ; ISSN: 0006-3002

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal LANGUAGE: English

Oxidation of unsatd. phosphatidylcholine (PC) produces fragmented phospholipids which have similar bioactivities as the platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-PC). Since a large number of mol. species are produced upon PC oxidation, the active ingredients have not been identified. We synthesized several short-chain PCs which are known to be characteristic PC oxidation products to test their PAF-like activity. The synthetic PCs contained palmitoyl or hexadecyl residues (both C16) in sn-1 position, and propionyl (C3), valeroyl (C5), succinyl (C4 with ω -carboxyl), glutarcyl (C5 with ω -carboxyl), or subercyl (C8 with ω -carboxyl) residues in sn-2 position. Biol. activity was measured by: (1) increase of intracellular calcium in human monocytes; (2) [3H] serotonin release from rabbit platelets; and (3) aggregation of human platelets. Specificity of the cellular response was tested by inhibition with the PAF-receptor antagonists BN 52021 and WEB 2086. Synthetic PC oxidation products activated both monocytes and platelets in a PAF-specific manner. The effective concentration varied with respect to assay system and chemical structure. In general, 1-hexadecyl-PCs were more effective than 1-palmitoyl-PCs, while increasing chain length in sn-2 position lowered biol. activity. However, several 1-palmitoy1-PCs activated monocytes in concns. between 10-8 and 10-6 M. In contrast, platelets were less susceptible to 1-palmitoyl-PCs. No significant difference was found. between 2-valeroyl-PC (C5 with ω -methyl) and 2-glutaroyl-PC (C5 with ω-carboxyl). The data suggest that typical products of PC oxidation, containing propionyl, succinyl, or glutaroyl residues in sn-2 position, display PAF-like activity at micromolar concns.

IT 217322-89-9

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(stimulation of monocytes and platelets by short-chain

phosphatidylcholines with and without terminal carboxyl group)

RN 217322-89-9 CAPLUS

CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 7-(4-carboxy-1-oxobutoxy)-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide (9CI) (CA INDEX NAME)

$$\begin{array}{c} O \\ || \\ HO_2C-(CH_2)_3-C-O \\ || \\ Me-(CH_2)_{15}-O-CH_2-CH-CH_2-O-P-O-CH_2-CH_2-N+Me_3 \\ || \\ O \end{array}$$

27

REFERENCE COUNT:

ACCESSION NUMBER: 1990:77856 CAPLUS

DOCUMENT NUMBER: 112:77856

TITLE: Preparation of carboxyacylglycerosulfates and

-phosphates as phospholipase substrates

INVENTOR(S): Junius, Martina; Neumann, Ulrich; Von der Eltz,

Herbert

PATENT ASSIGNEE(S): Boehringer Mannheim G.m.b.H., Fed. Rep. Ger.

SOURCE: Eur. Pat. Appl., 13 pp.

CODEN: EPXXDW

DOCUMENT TYPE:

LANGUAGE:

Patent German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 331167	A2	19890906	EP 1989-103660	19890302
EP 331167	A3	19891115		
EP 331167	B1	19920722		
R: AT, BE, CH,	DE, ES	, FR, GB, GR	, IT, LI, LU, NL, SE	
DE 3807123	A1	19890914	DE 1988-3807123	19880304
CA 1337656	A1	19951128	CA 1989-590628	19890209
JP 02003662	A2	19900109	JP 1989-46717	19890301
JP 04066864	B4	19921026		
AU 8930943	A1	19890907	AU 1989-30943	19890302
AU 600869	B2	19900823		
ZA 8901607	A	19891129	ZA 1989-1607	19890302
US 5091527	A	19920225	US 1989-318075	19890302
AT 78484	E	19920815	AT 1989-103660	19890302
ES 2034437	T3	19930401	ES 1989-103660	19890302
PRIORITY APPLN. INFO.:			DE 1988-3807123 A	19880304
			EP 1989-103660 A	19890302

OTHER SOURCE(S): CASREACT 112:77856; MARPAT 112:77856

AB (RYCH2) (ZOCH2) CHY1COACOX and [RYCH) (ZOCH2) CH2Y1COACOX [A = C1-16 alkylene, alkenylene; R = H, C1-20 alkyl, alkenyl, acyl, (alkyl-substituted) aryl, aralkyl; R1 = H, alkylamino; X = aryloxy, arylthio; Y, Y1 = O, S; Z = SO3-, P(:O) (O-)OR1], useful as substrates for determination of phospholipases, were prepared Thus, a mixture of 1-O-octadecyl-sn-glycero-3-phosphocholine, glutaric anhydride, and 4-dimethylaminopyridine was stirred 70 h in pyridine at 50° to give 1-O-octadecyl-2-(4-carboxybutyryl)-sn-glycero-3-phosphocholine. The latter in H2O/THF was stirred 40 h with 4-O2NC6H4OH and N-ethyl-N'-dimethylaminopropyl carbodimide at 60° to give 1-O-octadecyl-2-[4-(4-nitrophenoxy)carbonylbutyryl]-sn-glycero-3-phosphocholine.

IT 125001-84-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for phospholipase substrate)

RN 125001-84-5 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 7-(4-carboxy-1-oxobutoxy)-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (R)- (9CI) (CA INDEX NAME)

ACCESSION NUMBER:

1988:570803 CAPLUS

DOCUMENT NUMBER:

109:170803

TITLE:

Preparation of phospholipids for preparing platelet

activating factor antibody

INVENTOR (S): PATENT ASSIGNEE(S): Aono, Tetsuya; Nishikawa, Kohei

SOURCE:

Takeda Chemical Industries, Ltd., Japan Jpn. Kokai Tokkyo Koho, 7 pp.

CODEN: JKXXAF

DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63054386	A2	19880308	JP 1986-200335	19860826
PRIORITY APPLN. INFO.:			JP 1986-200335	19860826
OTHER SOURCE(S):	MARPAT	109:170803		

GΙ

AB The compds. I (m = integer), useful in the preparation of platelet activating factor antibodies, were prepared Hydrolysis of 2-benzyloxy-3-(7methoxycarbonylheptyloxy)propyl 2-trimethylammonioethyl phosphate (preparation given), followed by debenzylation and acetylation, gave 2-acetoxy-3-(7-carboxyheptyloxy)propyl 2-trimethylammonioethyl phosphate (II). Condensation of II with serum albumin produced a product for use in the production of platelet activating factor antibodies.

IT 117045-25-7DP, complexes with serum albumin

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, for preparation of platelet activating factor antibody)

RN 117045-25-7 CAPLUS

3,5,9-Trioxa-4-phosphanonacosan-1-aminium, 7-(acetyloxy)-29-carboxy-4-CN hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 1985:4277 CAPLUS

DOCUMENT NUMBER: 102:4277

AUTHOR (S):

SOURCE:

CORPORATE SOURCE:

TITLE: Phospholipase A2 activity of Fcy2b receptors of

> thioglycollate-elicited murine peritoneal macrophages Nitta, Toshimasa; Saito-Taki, Tatsuo; Suzuki, Tsuneo Med. Cent., Univ. Kansas, Kansas City, KS, 66103, USA Journal of Leukocyte Biology (1984), 36(4), 493-504

CODEN: JLBIE7; ISSN: 0741-5400

DOCUMENT TYPE: Journal LANGUAGE: English

AB The detergent lysate of a plastic-adherent cell population of thioglycollate-elicited peritoneal exudate cells from 100 individual Swiss mice was subjected to affinity chromatog. on 2 different media; Sepharose coupled to heat-aggregated human IgG (IgG-Sepharose), and Sepharose coupled to the phosphatidylcholine analog, rac-1-(9-carboxyl)nonyl-2hexadecylglycero-3-phosphorylcholine (PC-Sepharose). Both IgG- and PC-binding proteins were further purified by Sephadex G-100 gel filtration and isoelec. focusing in the presence of 6M urea. Both IgG- and PC-binding proteins thus purified appear to be homogeneous in size as well as charge properties. The IgG-binding proteins of PC-binding proteins of a mol. weight of 42,000 were more basic and had an isoelec. point of 6.0. Both materials retained their IgG-binding capabilities as judged by their inhibitory capacity of murine EAy rosetting systems. The subclass specificities of the IgG- and the PC-binding proteins were for IgG2a and IgG2b, resp. The PC-binding proteins possessed a typical phospholipase A2 activity, which was maximal at pH 9.5, depended on Ca2+, and was specific for cleavage of fatty acid from the sn-2 position of phosphatidylcholine. The binding of aggregated IgG2b to the PC-binding proteins caused a 9-fold increase in noted enzymic activity in the presence of, but not in the absence of, Ca2+ (5mM). The IgG-binding proteins on the other hand, lacked any detectable phospholipase A2 activity. Thus, the biochem. and biol. properties of the PC- and IgG-binding proteins isolated from murine peritoneal macrophages are essentially identical to those homologous proteins previously isolated from P388D1 cells.

IT 91921-89-0

RL: BIOL (Biological study)

(protein binding, on macrophage, phospholipase A2 of)

RN 91921-89-0 CAPLUS

CN 3,5,8-Trioxa-4-phosphatetracosan-1-aminium, 7-[[(9carboxynonyl)oxy]methyl]-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 1981:442295 CAPLUS

DOCUMENT NUMBER: 95:42295

TITLE: Synthesis of carboxyphospholipids

AUTHOR(S): Berchtold, Rudolf

CORPORATE SOURCE: Biochem. Lab., Berne, CH-3007, Switz.

SOURCE: Chemistry and Physics of Lipids (1981), 28(1), 55-60

CODEN: CPLIA4; ISSN: 0009-3084

DOCUMENT TYPE: Journal LANGUAGE: English

AB HO2C(CH2)10OCH2CH(OC16H33)CH2OP(O)(OH)OCH2CH2R (R = N+Me3OH-, NMe2, NHMe) (I) were prepared from HOCH2CH(OC16H33)CH2OCH2Ph by etherification with Br(CH2)10CO2Me, debenzylation by H and Pd-C catalyst, esterification with 2-bromoethyl phosphoryldichloride, amination and hydrolysis. the CO2H in I can bind the NH2 groups or certain protected NH2 groups of resins in column chromatog.

IT 78273-53-7P

RN 78273-53-7 CAPLUS

CN 3,5,8-Trioxa-4-phosphatetracosan-1-aminium, 7-[[(10-carboxydecyl)oxy]methyl]-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 1991:40661 CAPLUS

DOCUMENT NUMBER: 114:40661

TITLE: A facile synthesis of an aldehydic analog of platelet

activating factor and its use in the production of

specific antibodies

AUTHOR(S): Wang, Chang Jin; Tai, Hsin Hsiung

CORPORATE SOURCE: Coll. Pharm., Univ. Kentucky, Lexington, KY,

40536-0082, USA

SOURCE: Chemistry and Physics of Lipids (1990), 55(3), 265-73

CODEN: CPLIA4; ISSN: 0009-3084

DOCUMENT TYPE: Journal LANGUAGE: English

AB The multistep synthesis of a platelet activating factor (PAF) analog [Me3N+(CH2)2OP(O)(O-)OCH2CH(OAc)CH2O(CH2)8CHO] having a reactive aldehyde group at the ω-end of the sn-1 position is described. A novel ozonolysis of a double bond was employed to generate the aldehyde group in high yield under mild conditions. The aldehyde group was generated at the last step of the synthesis to avoid any reactions of protection and deprotection. The natural chiral center at the sn-2 position was introduced at the first step so that no steric resolution of the final product was needed. This analog of PAF was conjugated to thyroglobulin via reductive amination and then used to immunize rabbits for production of specific antibodies. The purified antibodies bind stereospecifically to tritiated PAF and crossreact minimally with lyso-PAF, plasmalogens and other phospholipids. The solid-phase RIA thus developed detects as low as 20 pg of PAF per assay tube and should be applicable to the quantitation of PAF in biol. systems.

IT 131418-02-5P

RN 131418-02-5 CAPLUS

CN 3,5,9-Trioxa-4-phosphaoctadecan-1-aminium, 7-(acetyloxy)-4-hydroxy-N,N,N-trimethyl-18-oxo-, inner salt, 4-oxide, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

IT 131418-02-5DP, reaction products with thyroglobulins
RL: PREP (Preparation)

(preparation of, in production of specific antibodies for RIA)

ACCESSION NUMBER: 1992:39343 CAPLUS

DOCUMENT NUMBER: 116:39343

TITLE: Antibodies to synthetic platelet-activating factor

(1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine)

analogs with substituents at the sn-2 position

AUTHOR(S): Karasawa, Ken; Satoh, Noriko; Masuda, Megumi; Setaka,

Morio; Hashimoto, Kikuo; Ishibashi, Kaichiro; Nojima,

Shoshichi

CORPORATE SOURCE: Fac. Pharm. Sci., Teikyo Univ., Sagamiko, 199-01,

Japan

SOURCE: Journal of Biochemistry (Tokyo, Japan) (1991), 110(5),

683-7

CODEN: JOBIAO; ISSN: 0021-924X

DOCUMENT TYPE: Journal LANGUAGE: English

AB The authors obtained rabbit antibodies by injecting immunogenic conjugates which were prepared by combining covalently 1-0-(15'-carboxypentadecyl)-2-0-

acetyl-sn-glycero-3-phosphocholine (acetyl-CPGPC), 1-O-(15'-carboxypentadecyl)-2-O-N, N-dimethylcarbamoyl-sn-glycero-3-

phosphocholine(dimethylcarbamoyl-CPGPC), or 1-O-(15'-carboxypentadecyl)-2-O-N-butylcarbamoyl-sn-glycero-3-phosphocholine (butylcarbamoyl-CPGPC) with protein (BSA or KLH), resp., and examined the specificity of the resulting antibodies by comparison with inhibition of the binding of iodolabeled CPGPC derivs. to the antibodies by corresponding or related phospholipids. Acetyl-CPGPC and dimethylcarbamoyl-CPGPC possessed haptenic activity causing production of antibodies reactive with PAF. Changes of the substituents at sn-2 in the antigens affected the specificity of the resulting antibodies. The affinity of the substituents to the antibodies decreased in the following order: acetyl » dimethylcarbamoyl and butylcarbamoyl for antibodies to acetyl-CPGPC-KLH; dimethylcarbamoyl > acetyl » butylcarbamoyl of antibodies to dimethylcarbamoyl-CPGPC-BSA; and butylcarbamoyl > dimethylcarbamoyl > acetyl for antibodies to

BSA; and butylcarbamoyl > dimethylcarbamoyl > acetyl for antibodies to butylcarbamoyl-CPGPC-BSA. Naturally occurring phospholipids, including lysoPAF, phosphatidylcholine, lysophosphatidylcholine, and sphingomyelin, revealed no cross-reactivities with these antibodies.

Anti-dimethylcarbamoyl-CPGPC-BSA IgG and anti-acetyl-CPGPC-KLH IgG

inhibited a PAF-induced aggregation of washed rabbit platelets in a dose-dependent manner. In contrast, anti-butylcarbamoyl-CPGPC-BSA IgG did not affect a PAF-induced platelet aggregation, nor did preimmune IgG.

IT 129879-41-0D, protein conjugates

RL: PRP (Properties)

(antibodies to, preparation and reactivity of, platelet-activating factor structure in relation to)

RN 129879-41-0 CAPLUS

CN 3,5,9-Trioxa-4-phosphatetracosan-1-aminium, 7-(acetyloxy)-24-carboxy-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (R)- (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 1992:468162 CAPLUS

DOCUMENT NUMBER: 117:68162

TITLE: Production and characterization of antibodies to

platelet-activating factor

AUTHOR(S): Macpherson, Janet L.; Spur, Bernt; Pyne, Stephen G.;

Heymans, Francoise; Cox, Marlene F.; Godfroid, Jean

Jaques; Krilis, Steven A.

CORPORATE SOURCE: Sch. Med., Univ. New South Wales, Kogarah, Australia

SOURCE: Journal of Lipid Mediators (1992), 5(1), 49-59

CODEN: JLMEEG; ISSN: 0921-8319

DOCUMENT TYPE: Journal LANGUAGE: English

AB Antibodies directed against platelet-activating factor (PAF) have been raised in rabbits immunized with a novel PAF-analog-conjugate. An analog of PAF with a C double bond at the terminal end of the alkyl chain was subjected to ozonolysis and converted to the aldehyde. The aldehyde was coupled to thyroglobulin by reductive alkylation and rabbits were immunized via either i.m. or intradermal routes in complete Freund's adjuvant. The antibodies are specific for PAF with a preference for the optically active (R)-enantiomer. There appears to be a requirement for antibody binding of ≤18 C alkyl at C1, and an acetyl group in the C2 position. The ability of a number of structural analogs to inhibit binding of tracer to the antibody is related to the biol. activity of the analog, and therefore may reflect the structural domains that are critical for PAF to interact with its receptors. An RIA was developed that is capable of detecting ≥0.3 pmol PAF/tube. Lyso-PAF does not interfere even at 25 µg/mL.

IT 142609-67-4DP, thyroglobulin conjugates

RL: PREP (Preparation)

(preparation of and antibodies to platelet-activating factor generation with)

RN 142609-67-4 CAPLUS

CN 3,5,9-Trioxa-4-phosphanonadecan-1-aminium, 7-(acetyloxy)-4-hydroxy-N,N,N-trimethyl-19-oxo-, inner salt, 4-oxide, (R)- (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 1989:592750 CAPLUS

DOCUMENT NUMBER: 111:192750

TITLE: Production of antibodies to platelet activating factor

AUTHOR(S): Smal, Mary A.; Baldo, Brian A.; Redmond, John W.
CORPORATE SOURCE: Kolling Inst. Med. Res., R. North Shore Hosp., St.

Leonards, 2065, Australia

SOURCE: Molecular Immunology (1989), 26(8), 711-19

CODEN: MOIMD5; ISSN: 0161-5890

DOCUMENT TYPE: Journal LANGUAGE: English

AB Elucidation of the pathophysiol. role of platelet activating factor (PAF) in health and disease is currently hampered by the lack of a sensitive, reproducible and easily applied assay for this potent phospholipid. This study describes the preparation of PAF in an immunogenic form, the production

of

antibodies to PAF and their use in the development of a preliminary RIA for PAF. Antibodies formed in response to a synthetic PAF analog coupled to a protein carrier were detected with 2 types of solid phases; PAF non-covalently adsorbed onto nitrocellulose and the PAF analog covalently linked to polyacrylamide. The latter was also used as a support for the isolation of anti-PAF antibodies by affinity chromatog. Quant. hapten inhibition studies showsed that the antibody combining sites were complementary to PAF and that corss-reactivity to lyso-PAF and some related phospholipids was negligible. Using these antibodies, [3H] PAF and Protein A-Sepharose as a means of separating bound and free tracer, the feasibility of developing a quant. RIA for PAF was demonstrated.

IT 119142-20-0P 123473-53-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and hydrolysis of)

RN 119142-20-0 CAPLUS

CN 2,9,13,15-Tetraoxa-14-phosphaheptadecan-17-aminium, 11-(acetyloxy)-14-hydroxy-3-methoxy-N,N,N-trimethyl-, inner salt, 14-oxide, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 123473-53-0 CAPLUS

CN 2,15,19,21-Tetraoxa-20-phosphatricosan-23-aminium, 17-(acetyloxy)-20-hydroxy-3-methoxy-N,N,N-trimethyl-, inner salt, 20-oxide, (R)- (9CI) (CALLINDEX NAME)

Absolute stereochemistry.

MeO
$$(CH_2)_{11}^{OMe}$$
 $(CH_2)_{11}^{OMe}$ $(CH_2)_{11}^{OMe}$

IT 119142-21-1DP, albumin and poly(Lys) conjugates 123473-54-1DP, albumin and poly(Lys) conjugates

RL: PREP (Preparation)

(preparation and platelet-activating factor-specific antibodies induction by)

RN 119142-21-1 CAPLUS

CN 3,5,9-Trioxa-4-phosphapentadecan-1-aminium, 7-(acetyloxy)-4-hydroxy-N,N,N-trimethyl-15-oxo-, inner salt, 4-oxide, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 123473-54-1 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheneicosan-1-aminium, 7-(acetyloxy)-4-hydroxy-N,N,N-trimethyl-21-oxo-, inner salt, 4-oxide, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

IT 119142-21-1P 123473-54-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction with proteins of)

RN 119142-21-1 CAPLUS

CN 3,5,9-Trioxa-4-phosphapentadecan-1-aminium, 7-(acetyloxy)-4-hydroxy-N,N,N-trimethyl-15-oxo-, inner salt, 4-oxide, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 123473-54-1 CAPLUS

CN 3,5,9-Trioxa-4-phosphaheneicosan-1-aminium, 7-(acetyloxy)-4-hydroxy-N,N,N-trimethyl-21-oxo-, inner salt, 4-oxide, (R)- (9CI) (CA INDEX NAME)